Literature DB >> 28199760

Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models.

Charlotte E Costentin1, Giuliana Amaddeo1, Thomas Decaens2, Karim Boudjema3, Philippe Bachellier4, Fabrice Muscari5, Ephrem Salamé6, Pierre-Henri Bernard7, Claire Francoz8, Sébastien Dharancy9, Claire Vanlemmens10, Sylvie Radenne11, Jérôme Dumortier12, Marie-Noelle Hilleret2, Olivier Chazouillères13, Georges P Pageaux14, Julien Calderaro15, Alexis Laurent16, Françoise Roudot-Thoraval1, Christophe Duvoux1.   

Abstract

AIM: Discordance between pre-LT imaging and explanted liver findings have been reported after liver transplantation (LT) for hepatocellular carcinoma (HCC), suggesting the need of reassessing the risk of HCC recurrence post-LT. Our aims were to compare pre-LT imaging and explants features and to test the performances of four explant-based predictive models of recurrence in an external cohort.
METHODS: Staging according to pre-LT imaging and explant features were compared. Four explants-based models were retrospectively tested in a cohort of 372 patients transplanted for HCC in 19 French centres between 2003 and 2005. Accuracies of the scores were compared.
RESULTS: Pre-LT imaging underestimated tumour burden in 83 (22.7%) patients according to Milan criteria. The highest AUCs for prediction of 5-years recurrence were observed in the "Up to seven" (0.7915 [95% CI: 0.7339-0.849]) and Decaens models (0.747 [95% CI: 0.6877-0.806]), with two levels of risk: low (10%) and high (>50%). Chan and Iwatsuki models identified 3 and 4 levels of risk, but had lower AUCs (0.68 and 0.70) respectively. Accuracy of the "Up to seven" model was superior to the Decaens model (P=.034), which was superior to the Chan model (P=.0041) but not to the Iwatsuki model (P=.17).
CONCLUSION: Pre-LT imaging underestimates tumour burden, and prediction of recurrence should be reassessed after LT. The explant-based "Up to seven" and Decaens models provided the best accuracy for prediction of 5-year recurrence, identifying only two levels of risk. New models are needed to further refine the prediction of recurrence after LT.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  explant pathology; hepatocellular carcinoma; liver transplantation; recurrence

Mesh:

Year:  2017        PMID: 28199760     DOI: 10.1111/liv.13388

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

Review 1.  Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Authors:  André Viveiros; Heinz Zoller; Armin Finkenstedt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-24

Review 2.  Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation.

Authors:  Russell E Rosenblatt; Zaid H Tafesh; Karim J Halazun
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

Review 3.  Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation.

Authors:  Helena Degroote; Anja Geerts; Xavier Verhelst; Hans Van Vlierberghe
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

4.  Preoperative blood neutrophil count predicts survival in hepatocellular carcinoma patients with living donor liver transplantation.

Authors:  Young Mi Hong; Mong Cho; Ki Tae Yoon; Je Ho Ryu; Kwang Ho Yang; Tae Ho Hwang
Journal:  Korean J Transplant       Date:  2020-06-30

5.  Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation.

Authors:  Deok Gie Kim; Jae Geun Lee; Dong Jin Joo; Soon Il Kim; Myoung Soo Kim
Journal:  Sci Rep       Date:  2019-07-17       Impact factor: 4.379

6.  Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience.

Authors:  Samir Zeair; Justyna Rajchert; Robert Stasiuk; Sławomir Cyprys; Janusz Miętkiewski; Katarzyna Zasada-Cedro; Ewa Karpińska; Marta Duczkowska; Miłosz Parczewski; Marta Wawrzynowicz-Syczewska
Journal:  Ann Transplant       Date:  2019-08-23       Impact factor: 1.530

7.  R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Charlotte Costentin; Federico Piñero; Helena Degroote; Andrea Notarpaolo; Ilka F Boin; Karim Boudjema; Cinzia Baccaro; Luis G Podestá; Philippe Bachellier; Giuseppe Maria Ettorre; Jaime Poniachik; Fabrice Muscari; Fabrizio Dibenedetto; Sergio Hoyos Duque; Ephrem Salame; Umberto Cillo; Sebastian Marciano; Claire Vanlemmens; Stefano Fagiuoli; Patrizia Burra; Hans Van Vlierberghe; Daniel Cherqui; Quirino Lai; Marcelo Silva; Fernando Rubinstein; Christophe Duvoux
Journal:  JHEP Rep       Date:  2022-02-02

8.  Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma.

Authors:  Astrid Herrero; Lucile Boivineau; Gianluca Cassese; Eric Assenat; Benjamin Riviere; Stéphanie Faure; José Ursic Bedoya; Fabrizio Panaro; Boris Guiu; Francis Navarro; Georges-Philippe Pageaux
Journal:  Transpl Int       Date:  2022-03-23       Impact factor: 3.782

9.  Nuclear morphometry and chromatin texture changes in hepatocellular carcinoma samples may predict outcomes of liver transplanted patients.

Authors:  Jordan Boeira Dos Santos; Rodrigo Tzovenos Starosta; Emily Ferreira Salles Pilar; Jefferson Daniel Kunz; Joelson Tomedi; Carlos Thadeu Schmidt Cerski; Rúbia Denise Ruppenthal
Journal:  BMC Gastroenterol       Date:  2022-04-15       Impact factor: 2.847

10.  Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model.

Authors:  Bleuenn Brusset; Jerome Dumortier; Daniel Cherqui; Georges-Philippe Pageaux; Emmanuel Boleslawski; Ludivine Chapron; Jean-Louis Quesada; Sylvie Radenne; Didier Samuel; Francis Navarro; Sebastien Dharancy; Thomas Decaens
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.